{"entity":{"id":"nct07752550","kind":"trial","name":"Retlirafusp Alfa Combined With Chemotherapy or Fuzuloparib for Triple-Negative Breast Cancer","aka":[],"tldr":"A phase 2 trial of retlirafusp alfa, nab-paclitaxel and fluzoparib in triple-negative breast cancer, run by Harbin Medical University, not yet recruiting.","summary":"Retlirafusp Alfa Combined With Chemotherapy or Fuzuloparib for Triple-Negative Breast Cancer is a phase 2, interventional study registered as NCT07752550 by Harbin Medical University, with a registry enrolment figure of 120 participants, started 2026-07-30 and due to reach its primary completion in 2028-07-30. Interventions recorded: Retlirafusp alfa+Nab-paclitaxel:; Retlirafusp alfa+Fluzoparib; Retlirafusp alfa+TP-AC; Retlirafusp alfa+Fluzoparib. Conditions listed: Triple-Negative Breast Cancer (TNBC). Triple-negative eligibility wording from the registry: \"Histopathologically confirmed recurrent or metastatic triple-negative breast cancer, defined as ER-negative (IHC ER-positive percentage \\<1%), PR-negative (IHC PR-positive percentage \\<1%), and HER2-negative (IHC -/+ or IHC ++ but FISH/CISH -);\". Sites: China. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07752550","url":"https://clinicaltrials.gov/study/NCT07752550"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-metastatic"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":["retlirafusp-alfa","nab-paclitaxel","fluzoparib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07752550","phase":"2","setting":"Retlirafusp Alfa Combined With Chemotherapy or Fuzuloparib for Triple-Negative Breast Cancer: An Exploratory Clinical Study","sponsor":"Harbin Medical University","enrolled":120,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07752550/","neighbours":{"cancer":[{"id":"tnbc-metastatic","kind":"cancer","name":"Metastatic triple-negative breast cancer","route":"/cancers/tnbc-metastatic/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"fluzoparib","kind":"drug","name":"Fluzoparib","route":"/drugs/fluzoparib/"},{"id":"nab-paclitaxel","kind":"drug","name":"Nab-paclitaxel","route":"/drugs/nab-paclitaxel/"},{"id":"retlirafusp-alfa","kind":"drug","name":"Retlirafusp alfa","route":"/drugs/retlirafusp-alfa/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}